

Pixie Dust Technologies (NASDAQ: PXDT)

Revenue & EPS Beat / Products Gaining Traction Quickly

Sector: Technology

Highlights

- In FY2024 (12 months ended April 2024), Pixie generated 993M yen (\$6.3M) in revenue, up 41% YoY, beating our estimate by 10%, driven by stronger unit sales of its flagship SonoRepro and kikippa products.
- EBITDA and EPS remained negative, and worsened slightly, due to a 20% increase in G&A expenses, driven by higher marketing expenses.
 2024 EPS was 7% higher than our estimate.
- Pixie has six commercialized products (all launched in the past two years), and several others in R&D stages. One of its flagship products promotes hair growth and mitigates hair loss (SonoRepro). The company also offers products to individuals who are deaf or hard of hearing (VUEVO), and those interested in improving their cognitive abilities (kikippa).
- In August 2024, the company launched the VUEVO Display, a transparent screen that shows real-time dialogue subtitles/translations on both sides. It is primarily designed for public transportation counters and hotel reception desks frequented by foreign visitors.
- Subsequent to year-end, Pixie secured a 1B yen loan from a mid-tier Japanese bank. Given that Pixie is still in early stages of revenue generation, it is encouraging to see the company vetted by a financial institution.
- Shares are down 82% YTD despite strong growth in revenue and recent product launches. We believe the market is underestimating the company's growth potential, particularly given the quick and promising early adoption of its products.

Key Financial Data (000s, JPY)						
YE: Apr 30th	2024	2025E	2026E			
Cash	1,607,763	775,555	26,930			
Working Capital	1,780,303	966,682	238,503			
LT-Debt	1,007,781	2,007,781	3,007,781			
Total Assets	3,382,601	2,587,147	1,871,623			
Revenue	993,021	1,410,938	1,763,672			
Net Income	(1,974,536)	(1,839,947)	(1,764,465)			
EPS	(138)	(128)	(123)			

*See last page for important disclosures, rating, and risk definitions. All figures in JPY unless otherwise specified.

BUY Current Price: US\$1.31 Fair Value: US\$4.45 Risk*: 4

Click here for more research on the company and to share your views

Sid Rajeev, B.Tech, CFA, MBA Head of Research



Company Data

52-Week Range	US\$1.13 - \$10.39
Shares O/S	15M
Market Cap.	US\$19M
Current Yield	N/A
P/E (forward)	N/A
P/B	2.0x



Company Overview

Formed in 2017

80 employees


Six commercialized products, and 10+ products in pipeline in various stages of R&D, all driven by Pixie's wave control technology

Follows an assetlight business model by relying on thirdparty manufacturers

Commercializing applications through partnerships with industry players, and research entities

> commercialized personal care products, all currently marketed in Japan

Three commercialized products for businesses, all available in Japan, with one also marketed in the U.S.



Headquartered in Tokyo, Pixie is focused on applying its proprietary wave control

technology across **a wide range of applications** for consumers and businesses. Wave control technology is **a proprietary innovation** capable of manipulating

sound and light waves to influence objects, gather and analyze their information,

Portfolio

and manipulate their features to achieve desired effects.

Source: Company



These three

FY2023)

products accounted for 65% of FY2024 revenue (57% in

Compared to typical startups, we believe

Pixie's strategic

potential by

expertise,

leveraging their

resources, and

SonoRepro is

for its ability to

marketed as a scalp

care device, while

stimulate a user's

auditory experience

kikippa is marketed

partnerships with

established players

enhance its success

distribution channels

The following section summarizes Pixie's flagship products.

SonoRepro (Launched in 2022)

Pixies has a non-exclusive distribution agreement with Angfa, a Japanese preventive medicine company; financial terms undisclosed





Source: Company

A <u>non-contact scalp care device</u> utilizing ultrasonic waves to stimulate the scalp, promoting hair growth and overall hair health; Intended for daily use, with each section requiring one minute of treatment.

Tests conducted by Pixie and its partner revealed significant improvements in hair diameter, scalp condition, and scalp water content.

Number of devices sold to date – 3,000+

Distribution - 95+ retail and online stores/salons in Japan, including major consumer electronics retail chains, and Amazon Japan (NASDAQ: AMZN)

Product Reviews - <10 reviews on Amazon, and other online stores

Device Price - 125,000 yen (US\$815)

Estimated product life - three years

Competition – Directly competes with hair scalp massagers offered by large brands; SonoRepro's advantages lie in its ability to stimulate the scalp without direct contact, ensuring cleanliness, and scalp protection. The price range of comparable devices is 85,000 (US\$550) to 200,000 yen (US\$1,300)

kikippa (Launched in 2023)

Developed in collaboration with **Shionogi Healthcare** (TSE: 4507/MCAP: US\$13B), a Japanese pharmaceutical company; financial terms undisclosed





Source: Company

An acoustic stimulation device/speaker primarily designed for seniors to enhance cognitive abilities and prevent dementia. This device uses a proprietary algorithm to transform everyday sounds (like those from TVs or computers) into frequencies associated with gamma brainwaves. Gamma waves are the fastest signals produced by the brain. Third-party studies indicate a link between gamma waves and improved cognitive functions. kikippa connects directly to audio devices.

Number of devices sold to date – undisclosed Distribution - Sold on partner Shionogi

Healthcare's online platform, consumer electronics stores, and other online stores

Product Reviews - <10 reviews on Amazon, and other online stores

Device Price - 90,000 yen (US\$590)

Estimated product life – five years

Competition – We are not aware of any direct competitors. However, the device competes with medical products/solutions designed for dementia prevention.

VUEVO (Launched in 2023)

Developed in collaboration with **Sumitomo Pharma** (TSE: 4506/MCAP: US\$1.8B), a Japanese pharmaceutical company; financial terms undisclosed





Source: Company

A tabletop microphone transcription service designed for the deaf and hard of hearing (DDH); it displays the direction and content of a speaker's voice in real-time. Compatible with computers and tablets, it enhances conversations in group settings like meetings or lectures. Pixie is currently developing smart glasses equipped with same technology.

In August 2024, the company launched the VUEVO Display, a transparent screen that shows real-time dialogue subtitles on both sides. It also features an interpretation for both DHH individuals and those speaking different languages.

Number of devices sold to date – in early stages of commercialization

Distribution – Direct sales to businesses

Product Reviews - N/A

Device Price – VUEVO mic: 145,000 yen (US\$945), and monthly usage fees of 30,000 yen (US\$195) for connectivity

Estimated product life – five years

Competition - Pixie competes with hearing aids and speech-to-text apps. Its advantages include distinguishing speakers in meetings, and value-added features such as summarized minutes. Pixie is in the process of incorporating translation services.



W

beat

YoY

2024

Financials (Year-End: Apr 30th) Segmented Results (000s, JPY)

	Services
FY2024 revenue vas up 41% YoY, ting our estimate by 10%	Products
	Revenue
	Services (incl. D&A)
	Products (incl. D&A)
	COGS (incl. D&A)
	Gross Profit
	Services - GM (incl. D&A)

Product sales were up 186% YoY, fueled by product launches in FY2023

Services revenue come from providing R&D services to partners; however, this revenue stream will likely diminish moving forward

EBITDA and EPS remained negative, and worsened slightly due to a 20% increase in G&A expenses, driven by higher marketing expenses

2024 EPS was 7% higher than expected

ices	512,772	636,265	521,7	763 46	69,867
ducts	-	-	182,9	949 52	23,154
enue	512,772	636,265	704,7	712 99	93,021
vices (incl. D&A)	136,390	206,604	65,6	605 4	45,474
ducts (incl. D&A)	-	-	77,0	035 28	86,428
iS (incl. D&A)	136,390	206,604	142,6	640 30	31,902
s Profit	376,382	429,661	562,0	072 66	61,119
vices - GM (incl. D&A)	73%	68%	8	7%	90%
ducts - GM (incl. D&A)	-	-	5	8%	45%
s Margin (Overall) - incl. D&A	73%	68%	8	0%	67%
Segmented Results		2023	2024	% of Total	ϒ៰ϒ
SonoRepro					
* Products Sold		1,432	1,545		<mark>8%</mark>
* Revenue (000s, JPY)		142,449	198,556	20%	39%
kikippa (Revenue - 000s, JPY)		170,008	386,795	39%	128%
VUEVO (Revenue - 000s, JPY)		89,725	64,209	6%	-28%
iwasemi					
* Products Sold		9,706	33,635		247%
* Physical dimensions (m2)		3,802	13,424		253%
* Revenue (000s, JPY)		57,440	130,768	13%	128%
KOTOWARI (Revenue - 000s, JPY)		122,704	166,427	17%	36%
Others (000s, JPY)		122,386	46,266	5%	
Total Revenue (000s, JPY)		704,712	993,021		41%
INCOME STATEMENTS (000s, JPY)					
YE: Apr 30th	2021	2022	2023	202	4 ΥοΥ
Revenue	512,772	636,265	704,712	993,02	1 41%
Cost of Sales	84,658	131,458	32,064	142,18	4 343%
Gross Profit	428,114	504,807	672,648	850,83	7 26%
G & A	EDE 150	022.205	1 700 510	0 150 00	3 20%
	525,158	833,305	1,790,519	2,152,28	2070
	601 731	694 072	686 557	512 99	7 -25%
R & D EBITDA	601,731 (698,775)	694,072 (1,022,570)	686,557 (1,804,428)		
				(1,814,443	3) 1%
EBITDA	(698,775)	(1,022,570)	(1,804,428)	(1,814,443 189,71	8) 1% 8 72%
EBITDA D&A	(698,775) 51,732	(1,022,570) 75,182	(1,804,428) 110,576	(1,814,443 189,71 (2,004,161	8) 1% 8 72% 1) 5%
EBITDA D&A EBIT	(698,775) 51,732 (750,507)	(1,022,570) 75,182 (1,097,752)	(1,804,428) 110,576 (1,915,004)	(1,814,443 189,71 (2,004,161 31,36	 1% 72% 5 9%
EBITDA D&A EBIT Interest	(698,775) 51,732 (750,507) 17,672	(1,022,570) 75,182 (1,097,752) 24,777	(1,804,428) 110,576 (1,915,004) 28,748	(1,814,443 189,71 (2,004,161 31,36 (2,035,526	8) 1% 8 72% 1) 5% 5 9% 5) 5%
EBITDA D&A EBIT Interest EBT	(698,775) 51,732 (750,507) 17,672	(1,022,570) 75,182 (1,097,752) 24,777	(1,804,428) 110,576 (1,915,004) 28,748 (1,943,752)	(1,814,443 189,71 (2,004,161 31,36 (2,035,526 3,57	B) 1% 8 72% 1) 5% 5 9% 5) 5% 7) -95%
EBITDA D&A EBIT Interest EBT Share-Based Compensation Unusual/Non-Recurring Expenses Income Tax	(698,775) 51,732 (750,507) 17,672 (768,179)	(1,022,570) 75,182 (1,097,752) 24,777 (1,122,529) - (13,025)	(1,804,428) 110,576 (1,915,004) 28,748 (1,943,752) 65,537 (43,798)	(1,814,443 189,71 (2,004,161 31,36 (2,035,526 3,57 (64,567	1% 8 72% 1) 5% 5 9% 6) 5% 7 -95% 7) 47%
EBITDA D&A EBIT Interest EBT Share-Based Compensation Unusual/Non-Recurring Expenses	(698,775) 51,732 (750,507) 17,672 (768,179)	(1,022,570) 75,182 (1,097,752) 24,777 (1,122,529)	(1,804,428) 110,576 (1,915,004) 28,748 (1,943,752) 65,537	(1,814,443 189,71 (2,004,161 31,36 (2,035,526 3,57 (64,567 (1,974,536	3) 1% 8 72% 9) 5% 5 9% 6) 5% 7 -95% 7) 47% 6) 0%

2021

2022

2023

Source: Company Filings, FRC



The company does not disclose its marketing expenses; In FY2024, G&A expenses (including marketing) were 217% of revenue, down from 254% in FY2023

With rising revenue, we believe this ratio will decrease to 156% in FY2025, and continue to trend lower

Established companies in the Healthcare Equipment/Services sector typically allocate 5%-10% of revenue to marketing expenses

FCF decreased due to higher G&A expenses

> Healthy balance sheet

Margins	2021	2022	2023	2024	Sector
Gross	83%	79%	95%	86%	26%
EBITDA	-136%	-161%	-256%	-183%	11%
EBIT	-146%	-173%	-272%	-202%	8%
Net	-148%	-174%	-279%	-199%	5%
Expenses (% of Revenue)	2021	2022	2023	2024	Sector
G & A	102%	131%	254%	217%	16%
R & D	117%	109%	97%	52%	

Summary of Cash Flows (000s, JPY)	0004	0000	0000	0004
YE: Apr 30th	2021	2022	2023	2024
Cash Flows from Operations	(589,065)	(1,075,326)	(1,813,442)	(2,090,202)
Cash Flows from Investing	779,350	(74,702)	(89,284)	(183,911)
Cash Flows from Financing	289,354	(120,110)	2,242,276	1,711,752
Net Change	479,639	(1,270,138)	339,550	(562,361)
Free Cash Flows	(607,642)	(1,145,810)	(1,893,802)	(2,263,080)

Liquidity & Capital Structure (000s, JPY) YE: Apr 30th	2022	2023	2024	Sector (Healthcare Equipment/Services)
Cash	1,795,963	2,135,513	1,607,763	
Working Capital	1,791,708	1,277,792	1,780,303	
Current Ratio	6.76	1.72	4.88	1.70
Total Debt	790,000	1,034,445	1,021,113	
Total Debt / Capital	33%	35%	42%	23%
LT Debt / Capital	32%	1%	41%	15%

	Warrants	S	trike Price	Value
	3,600		\$1.38	\$4,966
	93,000		\$0.18	\$17,186
	234,000		\$1.98	\$463,320
	30,000		\$1.99	\$59,796
	422,400		\$1.99	\$841,928
	219,600		\$1.99	\$437,707
	87,600		\$0.01	\$578
Total Outstanding	1,090,200		\$1.67	\$1,825,481
In-the-Money	180,600		\$0.10	17,765
-				

Source: Company Filings, FRC



FRC Projections and Valuation

As FY2024 G&A expenses were higher than expected, we are lowering our 2025 EPS estimate

As a result, our DCF valuation decreased from US\$6.19 to US\$5.70/share

We are not making any material changes to our revenue forecasts, with our models predicting that Pixie's two flagship products will capture 1% of their target markets in Japan by 2030, without considering any international expansion

For conservatism, we are not assigning any upside from the company's other products

JPY, 000s (except El	PS) 2025	E (Old) 202	5E (New)	2026E	(Introducing)	
Revenue	1,4	10,938	1,410,938		1,763,672	
EBITDA	-1,3	66,273 -	1,564,687		-1,429,246	
Net Profit	-1,6	82,512 -	1,839,947		-1,764,465	
EPS	-	113.19	-128.14		-122.88	
SonoRepro	2025E	2026E		2030E	Target	Markets
Unit Sales	6,563	8,203	3	30,429	2	2,760,000
Price (Yen)	125,000	125,000		125,000		125,000
Revenue (Yen)	820,312,500	1,025,390,628	3,80	3,625,000	345,000	0,000,000
kikippa						
Unit Sales	6,563	8,203	3	39,911	:	3,620,000
Price (Yen)	90,000	90,000		90,000		90,000
Revenue (Yen)	590,625,000	738,281,250	3,59	1,945,000	325,800	0,000,000
Service Revenue (Yen)	48,953,333	24,476,667	2 2	4,476,667	24	4,476,667
Total Revenue (Yen)	1,410,937,500	1,763,671,875	5 7,39	5,570,000	670,800	0,000,000

DCF Model (000s, JPY)	2025E	2026E	2030E	Terminal		
EBIT (1-tax)	(1,763,891)	(1,638,410)	1,947,873			
Non-Cash Expenses	199,204	209,164	254,240			
Change in Working Capital	(18,587)	(20,446)	(29,935)			
Cash from Operations	(1,583,274)	(1,449,691)	2,172,179			
CAPEX	(172,878)	(172,878)	(172,878)			
Free Cash Flow	(1,756,152)	(1,622,569)	1,999,301			
Present Value	(1,613,053)	(1,330,674)	1,042,016	11,925,297		
Discount Rate	12%					
Terminal Growth	3%					
Present Value (000s, JPY)	11,842,545					
Cash - Debt (000s, JPY)	586,650					
Fair Value (US\$)	\$85,761,442					
Shares O/S	15,036,106					
Value per Share (US\$)	\$5.70					
Source: FRC						




Pixie vs Major Consumer Electronics/Healthcare Equipment Companies	EV/Revenue (forward)
Intuitive Surgical	20.80
Boston Scientific	7.67
Andon Health	5.10
Abbott Laboratories	4.89
Johnson & Johnson	4.65
Medtronic	3.98
GE HealthCare	2.35
Sony	1.57
InMode	1.53
Cosonic Intelligent	1.40
Samsung	1.40
Koninklijke Philips	1.30
Pixie Dust (PV of 2027E)	0.86x
Healthcare Equipment/Services Sector	1.40x
Consumer Electronics Sector	0.90x
Average	2.41x
Pixie's Discount	-64%

Comparables Valuation

Source: FRC/S&P Capital IQ

We are **reiterating our BUY rating**, and adjusting our fair value estimate from US\$5.21 to US\$4.45/share (the average of our DCF and comparables valuations). Our valuation hinges heavily on the success of Pixie's two flagship products. While Pixie's technology is a recent innovation, we believe that product distribution by major Japanese retail chains and electronic stores, coupled with strong sales growth, **suggests promising market acceptance**.



Pixie is trading at 0.9x forward revenue (previously 1.4x) vs the sector average of 2.4x (previously 2.8x), implying a 64% discount

Applying 2.4x to our revenue forecast for Pixie, we arrived at a comparables valuation of US\$3.19/share (previously US\$4.23/share)

Our valuation is highly sensitive to our market share assumptions



Risks

We believe the company is exposed to the following key risks (not exhaustive):

- Limited operational history
- EBITDA has not yet turned positive
- We are maintaining our risk rating of 4 • Competition

(Speculative)

- Need to **pursue equity financings** to fund working capital, and R&D, until EBITDA turns positive
- No guarantee that the company will be able to expand its products internationally





	Appendix		
INCOME STATEMENTS (000s, JPY)	2024	2025E	2026E
YE: Apr 30th			
Revenue	993,021	1,410,938	1,763,672
Cost of Sales	142,184	282,188	705,469
Gross Profit	850,837	1,128,750	1,058,203
G & A	2,152,283	2,206,090	1,985, <mark>4</mark> 81
R&D	512,997	487,347	501,968
EBITDA	(1,814,443)	(1,564,687)	(1,429,246)
D&A	189,718	199,204	209,164
EBIT	(2,004,161)	(1,763,891)	(1,638,410)
Interest	31,365	76,056	126,056
ЕВТ	(2,035,526)	(1,839,947)	(1,764,465)
Share-Based Compensation	3,577		
Unusual/Non-Recurring Expenses	(64,567)		
Income Tax			
Net Income	(1,974,536)	(1,839,947)	(1,764,465)
EPS	-137.51	-128.14	-122.88
BALANCE SHEETS (000s, JPY) YE: Apr 30th	2024	2025E	2026E
Cash	1,607,763	775,555	26,930
A/R & Others	472,015	519,217	571,138
Inventories	158,780	174,658	192,124
Current Assets	2,238,558	1,469,429	790,192
PP&E	576,868	550,542	514,256
Others	567,175	567,175	567,175
Total Assets	3,382,601	2,587,147	1,871,623
Debt	13,332	13,332	13,332
A/P & Others	444,923	489,415	538,357
Current Liabilities	458,255	502,747	551,689
Debt	1,007,781	2,007,781	3,007,781
Others	491,068	491,068	491,068
Total Liabilities	1,957,104	3,001,596	4,050,538
Share Capital	7,782,285	7,782,285	7,782,285
Retained Earnings	-6,356,788	-8,196,735	-9,961,200
Total Liabilities & SE	3,382,601	2,587,147	1,871,623

"21+ Years of Bringing Undiscovered Investment Opportunities to the Forefront"



CASH FLOW STATEMENTS (000s, JPY)			
YE: Apr 30th	2024	2025E	2026E
Net loss for the period	-1,974,536	-1,839,947	-1,764,465
Items not involving cash			
D&A	189,718	199,204	209,164
Share-Based Compensation	3,577		
Others	-54,378		
FFO	-1,835,619	-1,640,743	-1,555,301
Changes in WC	-254,583	-18,587	-20,446
Cash From Operating Activities	-2,090,202	-1,659,330	-1,575,747
PP&E	-172,878	-172,878	-172,878
Others	-11,033		
Cash For Investing Activities	-183,911	-172,878	-172,878
Equity	1,740,123		
Debt	-13,332	1,000,000	1,000,000
Others	-15,039		
Cash From Financing Activities	1,711,752	1,000,000	1,000,000



Fundamental Research Corp. Equity Rating Scale:

Buy – Annual expected rate of return exceeds 12% or the expected return is commensurate with risk
 Hold – Annual expected rate of return is between 5% and 12%
 Sell – Annual expected rate of return is below 5% or the expected return is not commensurate with risk
 Suspended or Rating N/A— Coverage and ratings suspended until more information can be obtained from the company regarding recent events.

Fundamental Research Corp. Risk Rating Scale:

1 (Low Risk) - The company operates in an industry where it has a strong position (for example a monopoly, high market share etc.) or operates in a regulated industry. The future outlook is stable or positive for the industry. The company generates positive free cash flow and has a history of profitability. The capital structure is conservative with little or no debt.

2 (Below Average Risk) - The company operates in an industry where the fundamentals and outlook are positive. The industry and company are relatively less sensitive to systematic risk than companies with a Risk Rating of 3. The company has a history of profitability and has demonstrated its ability to generate positive free cash flows (though current free cash flow may be negative due to capital investment). The company's capital structure is conservative with little to modest use of debt.

3 (Average Risk) - The company operates in an industry that has average sensitivity to systematic risk. The industry may be cyclical. Profits and cash flow are sensitive to economic factors although the company has demonstrated its ability to generate positive earnings and cash flow. Debt use is in line with industry averages, and coverage ratios are sufficient.

4 (Speculative) - The company has little or no history of generating earnings or cash flow. Debt use is higher. These companies may be in start-up mode or in a turnaround situation. These companies should be considered speculative.

5 (Highly Speculative) - The company has no history of generating earnings or cash flow. They may operate in a new industry with new, and unproven products. Products may be at the development stage, testing, or seeking regulatory approval. These companies may run into liquidity issues and may rely on external funding. These stocks are considered highly speculative.

Disclaimers and Disclosure

The opinions expressed in this report are the true opinions of the analyst about this company and industry. Any "forward looking statements" are our best estimates and opinions based upon information that is publicly available and that we believe to be correct, but we have not independently verified with respect to truth or correctness. There is no guarantee that our forecasts will materialize. Actual results will likely vary. The analyst and Fundamental Research Corp. "FRC" does not own any shares of the subject company, does not make a market or offer shares for sale of the subject company, and does not have any investment banking business with the subject company. Fees were paid by PXDT to FRC. The purpose of the fee is to subsidize the high costs of research and monitoring. FRC takes steps to ensure independence including setting fees in advance and utilizing analysts who must abide by CFA Institute Code of Ethics and Standards of Professional Conduct. Additionally, analysts may not trade in any security under coverage. Our full editorial control of all research, timing of release of the reports, and release of liability for negative reports are protected contractually. To further ensure independence, PXDT has agreed to a minimum coverage term including an initial report and three updates. Coverage cannot be unilaterally terminated. Distribution procedure: our reports are distributed first to our web-based subscribers on the date shown on this report then made available to delayed access users through various other channels for a limited time.

The distribution of FRC's ratings are as follows: BUY (67%), HOLD (3%), SELL / SUSPEND (30%).

To subscribe for real-time access to research, visit https://www.researchfrc.com/website/subscribe/ for subscription options.

This report contains "forward looking" statements. Forward-looking statements regarding the Company and/or stock's performance inherently involve risks and uncertainties that could cause actual results to differ from such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's product/services in the marketplace; acceptance in the marketplace of the Company's new product lines/services; competitive factors; new product/service introductions by others; technological changes; dependence on suppliers; systematic market risks and other risks discussed in the Company's periodic report filings, including interim reports, annual reports, and annual information forms filed with the various securities regulators. By making these forward-looking statements, Fundamental Research Corp. and the analyst/author of this report undertakes no obligation to update these statements for revisions or changes after the date of this report. A report initiating coverage will most often be updated quarterly while a report issuing a rating may have no further or less frequent updates because the subject company is likely to be in earlier stages where nothing material may occur quarter to quarter.

Fundamental Research Corp DOES NOT MAKE ANY WARRANTIES, EXPRESSED OR IMPLIED, AS TO RESULTS TO BE OBTAINED FROM USING THIS INFORMATION AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OR FITNESS FOR A PARTICULAR USE. ANYONE USING THIS REPORT ASSUMES FULL RESPONSIBILITY FOR WHATEVER RESULTS THEY OBTAIN FROM WHATEVER USE THE INFORMATION WAS PUT TO. ALWAYS TALK TO YOUR FINANCIAL ADVISOR BEFORE YOU INVEST. WHETHER A STOCK SHOULD BE INCLUDED IN A PORTFOLIO DEPENDS ON ONE'S RISK TOLERANCE, OBJECTIVES, SITUATION, RETURN ON OTHER ASSETS, ETC. ONLY YOUR INVESTMENT ADVISOR WHO KNOWS YOUR UNIQUE CIRCUMSTANCES CAN MAKE A PROPER RECOMMENDATION AS TO THE MERIT OF ANY PARTICULAR SECURITY FOR INCLUSION IN YOUR PORTFOLIO. This REPORT is solely for informative purposes and is not a solicitation or an offer to buy or sell any security. It is not intended as being a complete description of the company, industry, securities or developments referred to in the material. Any forecasts contained in this report were independently prepared unless otherwise stated and HAVE NOT BEEN endorsed by the Management of the company which is the subject of this report. Additional information is available upon request. THIS REPORT IS COPYRIGHT. YOU MAY NOT REDISTRIBUTE THIS REPORT WITHOUT OUR PERMISSION. Please give proper credit, including citing Fundamental Research Corp and/or the analyst, when quoting information from this report.

The information contained in this report is intended to be viewed only in jurisdictions where it may be legally viewed and is not intended for use by any person or entity in any jurisdiction where such use would be contrary to local regulations or which would require any registration requirement within such jurisdiction.